C4 Therapeutics Inc
NASDAQ:CCCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
US |
|
S
|
Stadio Holdings Ltd
JSE:SDO
|
ZA |
|
S
|
Sugi Holdings Co Ltd
XMUN:UGI
|
JP |
|
Z
|
ZIM Integrated Shipping Services Ltd
F:2SV
|
IL |
|
HBT Financial Inc
F:9ND
|
US |
|
D
|
Davide Campari Milano NV
F:58H
|
IT |
|
Osmosun SA
F:V05
|
FR |
|
T
|
Tokyo Gas Co Ltd
XBER:TOG
|
JP |
|
S
|
Sinopharm Group Co Ltd
F:X2S
|
CN |
|
Aurora Innovation Inc
NASDAQ:AUR
|
US |
|
Central Garden & Pet Co
NASDAQ:CENT
|
US |
|
T
|
Take-Two Interactive Software Inc
XMUN:TKE
|
US |
|
M
|
Metso Outotec Corp
OTC:OUKPF
|
FI |
|
Bank Central Asia Tbk PT
IDX:BBCA
|
ID |
|
EDP Renovaveis SA
F:EDW0
|
ES |
|
N
|
Naturgy Energy Group SA
XMUN:GAN
|
ES |
|
P
|
Petroleo Brasileiro SA Petrobras
F:PJX
|
BR |
Wall St Price Targets
CCCC Price Targets Summary
C4 Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
CCCC is 13.6 USD with a low forecast of 7.07 USD and a high forecast of 31.5 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is CCCC's stock price target?
Price Target
13.6
USD
According to Wall Street analysts, the average 1-year price target for
CCCC is 13.6 USD with a low forecast of 7.07 USD and a high forecast of 31.5 USD.
What is the Revenue forecast for C4 Therapeutics Inc?
Projected CAGR
47%
Over the last 6 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 47%.